The abstract is read at the publisher; the summary is JClub's.
Moderate-to-heavy ethanol intake reduces anti-PD1 efficacy by ~50% in mouse models of lung and bladder cancers, increasing tumor recurrence and weakening antitumor immunity.
- Why it matters: Few advanced cancer patients achieve complete responses with immune checkpoint inhibition, and alcohol use is common while impairing adaptive immunity; the link to ICI benefit is unclear.
- What they did: Mice with lung and bladder tumors received moderate-to-heavy ethanol and anti-PD1 therapy, and tumor and immune features were profiled; a retrospective patient cohort receiving ICI was also assessed.
- The result: In patients with lung cancer, regular alcohol use is associated with reduced survival benefit from ICI, while mouse data show fewer TH17-favoring CD4+ T cells, fewer tissue-resident memory T cells, more TIGIT+ T cells, and improved PD1 blockade when TIGIT is blocked.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.